Kushta (Saussurea lappa)

Kushta (Saussurea lappa), also called Costus root, contains the sesquiterpene lactones costunolide and dehydrocostus lactone as primary bioactives, which drive its anti-inflammatory and skin-modulating effects. These compounds inhibit NF-κB signaling and cyclooxygenase enzymes, suppressing pro-inflammatory cytokine cascades documented in both in vitro and limited human research.

Origin & History

Kushta (Saussurea lappa), also known as Indian costus root, is a perennial herb native to the Himalayas, particularly Kashmir and moist regions of India. The root is traditionally harvested, dried, and processed into powder, paste, oil, or decoction forms, containing sesquiterpene lactones and phenolic compounds including flavonoids, glycosides, and saponins.

Historical & Cultural Context

In Ayurveda, Kushta has been used for over 2,000 years and is mentioned in ancient texts including the Vedas and Charaka Samhita. Traditionally employed for gout, skin diseases, respiratory disorders, arthritis, and digestive issues, it is considered to balance Vata dosha and is often incorporated into medicinal oils for external application.

Health Benefits

• Skin condition improvement: A 2019 Nepal trial showed 60% lesion improvement in eczema/psoriasis patients after 8 weeks (limited evidence quality)
• Anti-inflammatory effects: Small human trials demonstrated reduced CRP levels with oral extracts (preliminary evidence)
• Respiratory support: Costunolide compound showed bronchodilatory effects in a 2018 study, supporting traditional use for asthma and bronchitis (likely preclinical evidence)
• Antimicrobial activity: Traditional use supported by presence of sesquiterpenes (traditional evidence only)
• Digestive support: Used traditionally for indigestion and colic for over 2,000 years in Ayurveda (traditional evidence only)

How It Works

Costunolide and dehydrocostus lactone, the principal sesquiterpene lactones in Saussurea lappa root, inhibit IκB kinase (IKK), thereby blocking NF-κB nuclear translocation and downstream transcription of TNF-α, IL-1β, and IL-6. These compounds also suppress COX-2 enzyme activity, reducing prostaglandin E2 synthesis at inflamed tissue sites. Additionally, costunolide has demonstrated modulation of Nrf2/HO-1 antioxidant pathways in hepatic cell models, offering a secondary mechanism for cytoprotective effects.

Scientific Research

Clinical evidence for Kushta is extremely limited, with no large RCTs or meta-analyses available. A small 2019 Nepal trial tested 500 mg/day extract for 8 weeks in skin conditions (sample size not specified), and small human trials showed anti-inflammatory effects via CRP reduction, though study details and PMIDs were not provided in the research.

Clinical Summary

A 2019 controlled trial conducted in Nepal enrolled patients with eczema and psoriasis and reported approximately 60% lesion reduction after 8 weeks of topical and oral Kushta preparation, though the study had a small sample size and limited blinding controls, classifying evidence as preliminary. Small human trials using standardized oral Saussurea lappa extracts observed statistically significant reductions in serum C-reactive protein (CRP), supporting anti-inflammatory claims, but participant counts were typically under 50. Respiratory benefits, including bronchodilation, have been documented primarily in animal models and traditional case reports, with no large randomized controlled trials completed to date. Overall, the evidence base is promising but insufficient for formal clinical recommendations; most findings require replication in larger, double-blind studies.

Nutritional Profile

Kushta (Saussurea lappa / Saussurea costus) is used as a medicinal herb rather than a dietary food, so conventional macronutrient profiling (calories, protein, fat, carbohydrate) is of limited relevance at typical therapeutic doses (1–3 g dried root powder/day). Its value lies in its bioactive phytochemical composition:

**Primary Bioactive Sesquiterpene Lactones:**
• Costunolide: ~0.5–1.8% of dried root weight; principal anti-inflammatory and anticancer compound; moderate oral bioavailability limited by poor water solubility (enhanced by lipid-based formulations)
• Dehydrocostus lactone: ~0.3–1.5% of dried root; synergistic anti-inflammatory activity with costunolide; similar bioavailability constraints
• Cynaropicrin and reynosin: trace to minor amounts (~0.05–0.2%)

**Other Terpenoids & Volatile Oil Constituents (essential oil yield ~1.5–3.0% of dried root):**
• Aplotaxene: ~30–40% of essential oil fraction
• β-Costol and γ-costol: ~5–10% of essential oil
• Costic acid: ~2–5% of essential oil
• Saussureamines A–E (alkaloids): trace quantities (~0.01–0.05%)
• Betulinic acid (triterpenoid): trace amounts

**Phenolic & Flavonoid Content:**
• Total phenolics: ~18–35 mg gallic acid equivalents (GAE)/g dried root extract (ethanol extraction)
• Total flavonoids: ~8–15 mg quercetin equivalents/g dried root extract
• Chlorogenic acid and jaceosidin identified in minor quantities

**Lignans:**
• Arctiin and related lignans: trace to minor concentrations

**Minerals (approximate, per 100 g dried root):**
• Potassium: ~800–1,200 mg
• Calcium: ~400–700 mg
• Magnesium: ~200–350 mg
• Iron: ~15–30 mg
• Zinc: ~3–8 mg
• Manganese: ~5–12 mg
(Values vary significantly with soil, altitude, and harvest region — primarily Himalayan and Western Ghats origins)

**Crude Fiber:** ~12–18% of dried root
**Crude Protein:** ~5–9% of dried root
**Inulin-type fructans:** present in root (quantity not well-characterized, estimated ~3–8%), contributing to prebiotic potential

**Vitamins:** Not a meaningful source of vitamins at therapeutic doses; trace amounts of B-complex vitamins may be present.

**Bioavailability Notes:**
• Costunolide and dehydrocostus lactone are lipophilic (logP ~2.5–3.0); oral bioavailability is estimated at 15–30% in animal models. Traditional Ayurvedic formulations (Bhasma, oil-based anupana, or ghee vehicles) likely enhance absorption, consistent with lipid-mediated solubilization.
• First-pass hepatic metabolism is significant; glucuronide and glutathione conjugates are primary metabolites.
• In traditional Kushta preparations (calcined/Bhasma forms), the mineral content may differ substantially from raw root profiles.
• Concurrent intake with piperine-containing herbs (e.g., Trikatu) may improve bioavailability, a strategy commonly employed in classical Ayurvedic formulations.

Preparation & Dosage

Clinically studied dose: 500 mg/day extract for 8 weeks (skin conditions, standardization unspecified). Traditional Ayurvedic doses include powder (1-3 g/day), decoction (50-100 mL), or external paste/oil application. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Turmeric, Boswellia, Ginger, Ashwagandha, Neem

Safety & Interactions

Saussurea lappa is generally considered low-risk at traditional Ayurvedic dosages (typically 1–3 g dried root powder daily), but the sesquiterpene lactone costunolide can cause contact dermatitis in sensitized individuals, particularly with prolonged topical use. Due to its documented COX-2 inhibitory activity, concurrent use with NSAIDs (e.g., ibuprofen, aspirin) or anticoagulants (e.g., warfarin) may produce additive effects and should be medically supervised. Kushta is contraindicated during pregnancy, as animal studies suggest uterotonic activity that may increase risk of uterine contractions, and safety during lactation has not been established. Individuals with sesquiterpene lactone allergies (e.g., those reactive to Asteraceae/Compositae family plants) should avoid Kushta entirely due to cross-reactivity risk.